Business Context and Reporting Period
Company: OraSure Technologies, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2002
Business Overview: The Company develops, manufactures, and markets oral specimen collection devices, proprietary diagnostic products, and medical devices. Products are sold globally to clinical laboratories, physician offices, hospitals, and distributors.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2002 |
Six Months Ended June 30, 2002 |
Six Months Ended June 30, 2001 |
|---|---|---|---|
| Total Revenues | $7,930,032 | $15,655,506 | $15,911,820 |
| Gross Profit | $4,729,581 | $9,560,825 | $10,204,822 |
| Gross Margin | 60% | 61% | 64% |
| Operating Loss | $(1,354,548) | $(3,016,049) | $(1,829,010) |
| Net Loss | $(1,281,136) | $(2,873,833) | $(1,440,936) |
| Net Loss Per Share (Basic/Diluted) | $(0.03) | $(0.08) | $(0.04) |
| Cash and Cash Equivalents | $1,437,446 | $1,437,446 | $5,095,639 (Beginning of 2001 period) |
| Short-term Investments | $10,873,890 | $10,873,890 | $12,764,903 (Dec 31, 2001) |
| Total Debt (Current + Long-term) | $4,143,874 | $4,143,874 | $4,644,030 (Dec 31, 2001) |
| Working Capital | $17,003,159 | $17,003,159 | $19,763,940 (Dec 31, 2001) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 7% in the quarter and 2% in the six-month period compared to 2001. This was driven by an 87% drop in licensing and product development revenue (due to the absence of milestone payments received in 2001) and declines in insurance risk assessment and substance abuse testing markets.
- Market Shifts: Infectious disease testing revenues increased 22% (quarter) and 14% (six months) due to higher sales of OraSure oral fluid HIV-1 collection devices. Conversely, insurance risk assessment sales declined due to processing efficiencies at LabOne, Inc., the Company's largest customer.
- Margin Compression: Gross margin decreased from 65% to 60% (quarter) and 64% to 61% (six months), attributed to lower high-margin licensing revenue and higher scrap rates.
- Expense Increases: Sales and marketing expenses rose 16% (quarter) and 12% (six months) due to strategic marketing consulting fees. General and administrative expenses increased 16% for the six months, primarily due to a $480,063 severance charge for the former CEO.
- Cash Flow: Net cash used in operating activities was $1.98 million for the six months ended June 30, 2002, compared to $2.44 million in the prior year period. Cash and cash equivalents decreased by approximately $1 million during the period.
Guidance, Outlook, and Risks
- Abbott Laboratories Agreement: The Company expects to receive approximately $4.0 million in product revenues through the end of 2003 from a co-exclusive distribution agreement with Abbott Laboratories for the OraQuick(R) rapid HIV-1 test. This is contingent on final FDA approval, expected in the third quarter of 2002.
- Intercept(R) Growth: The Company anticipates increased revenues from the Intercept(R) drug testing system in the second half of 2002 and 2003 following the successful startup of sales efforts by three new laboratory distributors.
- Price Increase Impact: A price increase for the Histofreezer(R) system effective April 1, 2002, caused distributors to stock up in Q1. Sales are expected to return to a normal pattern in Q3 2002.
- Liquidity: The Company holds approximately $12.3 million in cash and short-term investments. It has a $1.0 million working capital line of credit and a $3.0 million equipment line of credit, both expiring August 31, 2002, with no current borrowings. Management expects these facilities to be replaced but notes no assurance of success.
- Risks: Key risks include the timing of FDA approvals, reliance on strategic partners (e.g., Abbott, LabOne), customer concentration (one customer accounted for 26% of Q2 revenue), and the ability to fund R&D and operations given the history of net losses.
Investor Verification Checklist
- FDA Approval Status: Verify the receipt of final FDA approval for the OraQuick(R) rapid HIV-1 test, which is critical for the projected $4.0 million revenue stream from Abbott.
- Customer Concentration: Monitor the financial health and purchasing volume of LabOne, Inc., which accounts for a significant portion of insurance risk assessment revenue and has recently reduced volumes due to efficiency gains.
- Debt Refinancing: Confirm the renewal or replacement of the $1.0 million working capital and $3.0 million equipment credit lines expiring in August 2002.
- Inventory Levels: Review inventory turnover and potential write-offs, as the Company noted higher scrap rates and an increase in inventory levels ($4.99 million at June 30, 2002 vs. $4.44 million at year-end 2001).
- Severance Costs: Note the one-time $480,063 severance expense for the former CEO included in the six-month results, which impacted G&A expenses.